Digital Academy

Frank Bennett, PhD, of Isis Pharmaceuticals, gives an update on the DMPK-RX clinical trial.

Click here to view slides from this presentation.

Chad Heatwole, MD, MS-CI, of the University of Rochester (presentation); Sarah Howe of the Marigold Foundation (presentation); Darren Monckton, PhD, of the University of Glasgow (presentation); and Cynthia Gagnon, PhD, OT, of the Université de Sherbrooke (presentation); discuss their current research projects and how they relate to the future of DM.

Moderated by Mel Kohn, MD, MPH, MDF Board Member.

MDF Fellows Ayal Hendel, PhD, Stanford University (presentation); Suzanne Rzuczek, PhD, Scripps Research Institute of Florida (presentation); Eric Wang, PhD, MIT (presentation); and Yao Yao, PhD, Rockefeller University (presentation); discuss their current research and where the future of DM science is heading.

Moderated by John Day, MD, PhD, Stanford University; and Charles Thorton, MD, University of Rochester.

Dr. Matt Disney and Dr. John Day provide an overview of the DM2 disease mechanism and describe how compounds can be designed as potential therapies for this disease.

Dr. Bruce Wentworth, Ph.D., of Genzyme, presents an overview of  ASO treatments, describing in lay language how they are intended to treat DM.

(View a PDF of Dr. Wentworth's presentation)

Pages